<b>Background/Objectives</b>: Ovarian function suppression (OFS) is part of endocrine therapy treatment for high-risk premenopausal women with hormone receptor-positive (HR+) breast cancer (BC). This evidence concerns the gene NR4A1 and breast carcinoma.